智通财经APP讯,广生堂(300436.SZ)公告,公司创新药控股子公司福建广生中霖生物科技有限公司的在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验,已于近日完成全部受试者入组,合计入组578例。
本次GST-HG141完成III期临床试验全部受试者入组后,尚需按照已制定临床方案和要求继续推进临床试验,并经国家药品审评部门注册审批通过后方可上市。
智通财经APP讯,广生堂(300436.SZ)公告,公司创新药控股子公司福建广生中霖生物科技有限公司的在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验,已于近日完成全部受试者入组,合计入组578例。
本次GST-HG141完成III期临床试验全部受试者入组后,尚需按照已制定临床方案和要求继续推进临床试验,并经国家药品审评部门注册审批通过后方可上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.